April 1, 1995Shock
Interleukin-1 and Interleukin-1 Antagonism in Sepsis, Systemic Inflammatory Response Syndrome, and Septic Shock
Authors
Discussion
Loading...
Member takes
Implication
Narrative review demonstrates the pathological role of excessive interleukin-1 in septic shock, highlighting the therapeutic potential of interleukin-1 receptor antagonism.
Key Points
- To review the biological role of interleukin-1 (IL-1) in sepsis, systemic inflammatory response syndrome (SIRS), and septic shock, and evaluate the therapeutic utility of IL-1 receptor antagonists.
- Synthesized findings from preclinical animal models and human clinical investigations evaluating IL-1 expression during systemic inflammation.
- Evaluated the molecular function and regulation of IL-1 receptors and endogenous IL-1 receptor antagonists in modulating inflammatory cascades.
- Excessive or prolonged IL-1 production directly induces severe systemic manifestations, including hypotension, multi-organ system failure, hematologic dyscrasia, and increased mortality.
- Targeted inhibition of IL-1 signaling via IL-1 receptor antagonists attenuates systemic inflammatory damage and shows potential for improving clinical outcomes in sepsis and septic shock.
Cite This Study
Pruitt et al. (1995) studied this question.